, the newly identified signal transducer with lipid phosphatase activity (47) ; and the tyrosine phosphatase SHP-1 (83) , which is phosphorylated upon CSF-1 stimulation but which does not associate with the CSF-1R (82, 84) . SHP-1 (otherwise known as SHPTP1, Hcp, and PTP1C) is a member of a family of cytosolic protein tyrosine phosphatases which contain SH2 domains. The expression of this phosphatase is restricted to epithelial and hematopoietic cells (reviewed in reference 25). In the latter cell type, SHP-1 appears to function in the differentiation, survival, and/or proliferation of cells of the erythroid and macrophage cell lineages as well as in the determination, differentiation, or selection of normal B cells. Mice harboring null or inactivating mutations in this gene (motheaten [ (63, 64, 73) are severely immunodeficient. me/me and me v /me v mice are affected with numerous anomalies of the hematopoietic system, such as an increase in the number of erythroid progenitor cells, monocytes, macrophages, and neutrophils. Consistently, bone marrow macrophages from me/me mice are hyperresponsive to CSF-1 in vitro (14) . In addition, in these mice the B-cell compartment shows an increased CD5 ϩ -cell/CD5 Ϫ -cell ratio, a phenotype that correlates with autoantibody production (reviewed in reference 5). In agreement with these phenotypes, SHP-1 has been reported to function in the negative regulation of signaling pathways in a number of hematopoietic systems.
The phosphatase forms complexes with several cell surface receptors: c-kit (84) , the interleukin-3 receptor ␤ subunit (85) , the erythropoietin receptor (37) , the alpha interferon receptor complex (19) , CD22, and Fc␥RIIB1 receptors (18, 21, 44, 55) . In some cases, SHP-1 has been shown to dephosphorylate the receptor itself (85) or the receptor-associated tyrosine kinases Jak-2 (37), Jak-1 (19) , and Tyk-2 (81), thereby down-regulating signaling (17, 18, 21, 37, 55, 85) . In addition, in activated mast cells and T lymphocytes SHP-1 reportedly associates with the product of the vav proto-oncogene (a putative guanine nucleotide exchange factor expressed in hematopoietic cells), as well as with Grb-2 and the Ras GTP-GDP exchange factor mSOS (38) . Of particularly relevance, while this article was being reviewed, association of tyrosine-phosphorylated SHP-1 with Grb-2 via the Grb-2 SH2 domain in macrophages was reported; in addition, a number of proteins that associated with the Grb-2 SH3 domain are hyperphosphorylated in macrophages from the me/me mouse mutant, suggesting that Grb-2 may recruit substrates for SHP-1 (14) .
The ubiquitously expressed counterpart of SHP-1 (known as PTP1D, Syp, SHPTP2, and PTP2C) has been shown to interact physically with and relay signals from tyrosine kinase receptors (34, 45, 46) or their substrates (41) to the Ras-mitogen-activated protein kinase (MAPK) pathway (2, 7, 22) in mammalian cells (51, 53, 77 ; reviewed in reference 71). Genetic evidence shows that the Drosophila melanogaster homolog corkscrew cooperates with D-raf in transducing signals from the torso receptor tyrosine kinase (56) .
We sought to determine whether SHP-1 may mediate some of its effects on hematopoietic cell growth and development through modulation of Ras activation. GTP loading of p21 ras and activation of cytosolic serine/threonine kinase cascades are among the early events in CSF-1-mediated signal transduction (4, 9) . Using a CSF-1-dependent macrophage cell line (BAC-1.2F5) as a model system, we have recently shown that expression of a dominant negative Ras mutant strongly reduces CSF-1-mediated stimulation of MEK (mitogen and extracellularsignal-activated protein kinase kinase) and MAPK. In contrast, activation of the serine/threonine kinase Raf-1 is Ras independent (9) . We now extend these data, showing that SHP-1 is activated in the course of mitogenic signal transduction in a Ras-dependent manner and that phosphatase activity is necessary for the activation of the MAPK pathway but not of the Raf-1 kinase. Lipopolysaccharide (LPS)-mediated activation of the MAPK pathway proved to be independent of Ras and SHP-1 activation and was consistently intact in macrophages derived from the me v /me v mice.
MATERIALS AND METHODS
Cell culture and stimulation. Bone marrow macrophages were obtained by standard techniques (20) . Primary macrophages, BAC-1.2F5 cells (52) , and the stable cell line BAC Asn17 (9), harboring the Ras-N17 construct expressed via the glucocorticoid-inducible mouse mammary tumor virus promoter (10), were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 20% L-cell-conditioned medium as a source of CSF-1 (68) . Confluent cultures (10 7 cells per 100-mm-diameter tissue culture dish) were cultured in medium without CSF-1 for 16 h to up-regulate CSF-1 receptors and then incubated for different periods with either 1 g of bacterial LPS (from Escherichia coli O111:B4; Sigma, Deisenhofen, Germany) per ml, 0.63 nM mouse recombinant CSF-1 (39), or 6.3 nM human recombinant CSF-1 (kind gift from Jolanda Schreurs, Chiron Co.).
Cell lysis, immunoprecipitation, and immune complex kinase and phosphatase assays. Cell lysis and immunoprecipitation were performed exactly as previously described (3) . In the case of the SHP-1 immune complexes to be used in the phosphatase assays, sodium orthovanadate was omitted from the lysis buffer. SHP-1 was immunoprecipitated with a polyclonal antiserum directed against a unique carboxyl-terminal peptide of SHP-1 (82) .
A rabbit polyclonal antiserum raised against a carboxy-terminal peptide of v-raf (SP63, CTLTTSPRLPVF) (62) was used to immunoprecipitate Raf-1 molecules. MEK-1 and MEK-2 were immunoprecipitated with a rabbit polyclonal antibody (Affiniti, Nottingham, United Kingdom). Immune complexes were collected following incubation (1 h at 4ЊC) with protein A-Sepharose beads (Sigma).
Raf-1 and MEK immune complex kinase assays were carried out exactly as described previously (9) . In addition, in selected experiments Raf-1 activity was assessed by its ability to activate MEK in a coupled assay (1) . The activity of SHP-1 immunoprecipitates was assayed by a previously described colorimetric assay using p-nitrophenyl phosphate as a substrate (74) .
"In-gel" kinase assay. Samples containing 7.5 g of protein were added to 62.5 mM Tris (pH 6.8)-2.3% sodium dodecyl sulfate (SDS)-5 mM EDTA-10% glycerol-100 mM dithiothreitol and heated at 85ЊC for 5 min before SDSpolyacrylamide gel electrophoresis (SDS-PAGE). The separating gels were polymerized with 0.2 mg of myelin basic protein (Sigma) per ml, and after electrophoresis they were denatured in 6 M guanidine HCl, renatured, and assayed for kinase activity as described previously (12) .
Analysis of nucleotides bound to p21 ras . The fraction of p21 ras bound to GDP or to GTP was determined as previously described (78) . Confluent cells were incubated in phosphate-free Dulbecco's modified Eagle's medium supplemented with 10% dialyzed fetal calf serum in the absence of CSF-1 for 16 h and subsequently labeled by incubation for 4 h in phosphate-free medium containing 2.6 mM NaHCO 3 and 250 Ci of carrier-free o- [ 32 P]phosphate (9,000 Ci/mmol; Amersham, Little Chalfont, Buckinghamshire, United Kingdom) per ml. Labeling media were supplemented with 25 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) buffer and 10% dialyzed fetal calf serum. After stimulation with CSF-1 the cells were washed three times with ice-cold phosphatebuffered saline (PBS) and scraped in 1 ml of lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 20 mM MgCl 2 , 1% Nonidet P-40, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and 1% aprotinin) supplemented with 2 g of Ras antibody Y13-259 per ml. The extracts were mixed thoroughly and incubated at 4ЊC for 30 min. After centrifugation, the supernatants were mixed with 40 l of protein A-Sepharose and 10 g of rabbit anti-rat immunoglobulin G. Following a 30-min incubation at 4ЊC, immunoprecipitates were collected by centrifugation and washed twice with lysis buffer and three times with PBS. The pellets were resuspended in 25 l of 0.75 M KH 2 PO 4 (pH 3.4)-5 mM EDTA-0.1 mM GDP-0.1 mM GTP and heated at 75ЊC for 5 min. Equal counts of the supernatants were spotted onto polyethyleneimine cellulose thin-layer plates and developed with 1 M KH 2 PO 4 (pH 4).
RESULTS
Lack of SHP-1 activation and tyrosine phosphorylation in CSF-1-treated, bone marrow-derived macrophages from me v / me v mice. The me v mutation (T-to-A transversion) destroys a splice donor site in the SHP-1 gene. This results in the activation of cryptic splicing sites and in either an in-frame insertion or a deletion in the tyrosine phosphatase catalytic domain. As a result, two SHP-1 proteins are present in bone marrowderived me v /me v macrophages. The deletion product is expressed in much larger amounts than the insertion product, which becomes visible only upon longer exposure (Fig. 1A ) (64) . Both mutations have a severely deleterious effect on the activity of the enzyme ( macrophages from C57BL/6J or me v /me v mice were treated with CSF-1 for different time periods prior to cell lysis and SHP-1 immunoprecipitation. The activity of the enzyme was then determined in immune complex phosphatase assays with p-nitrophenyl phosphate as a substrate. As expected, the activity of SHP-1 immunoisolated from quiescent and CSF-1-stimulated me v /me v mouse-derived macrophages was severely impaired compared with the controls (Fig. 1B) . The deletion products, and much more so the insertion products, showed constitutive tyrosine phosphorylation, possibly as a result of the lack of autodephosphorylation; it is worth noting that the insertion form is expressed at an extremely low level but is much more tyrosine phosphorylated than the deletion form (compare Fig. 1A and B). Remarkably, neither of the mutant proteins was additionally phosphorylated on tyrosine upon CSF-1 stimulation (Fig. 1C ). This indicates either that the structural changes in the catalytic domain render the enzyme refractory to growth factor-induced tyrosine phosphorylation or that the absence of SHP-1 function causes a change in the activation of the CSF-1R and/or of downstream kinases involved in the phosphorylation of the phosphatase. It should be noted here, however, that we did not observe major differences in the tyrosine phosphorylation of the CSF-1R in me v /me v mouse-derived macrophages compared with the controls at the saturating CSF-1 concentrations used (data not shown). In me/me mouse-derived macrophages, several proteins are hyperphosphorylated on tyrosine residues (14) . In contrast, only two proteins (p130 and p60) are hyperphosphorylated in lysates from me v /me v mouse-derived macrophages (data not shown). The possibility that these proteins may represent SHP-1 targets is currently being investigated.
Effect of the me v /me v mutation on the CSF-1-induced activation of MEK, MAPK, and Raf-1 kinase. We next investigated whether SHP-1 functioned in the pathway leading to the activation of cytosolic serine/threonine kinases. MEK activity was measured in immune complex kinase assays with bacterially expressed, catalytically compromised ERK-2 as a MEK substrate. The antiserum used in this assay recognizes MEK-1 and MEK-2. The activity of MAPK was visualized by an in-gel kinase assay. This technique allows the assessment of MAPK activity in whole-cell extracts. The extracts were resolved by SDS-PAGE in a gel containing myelin basic protein. After renaturation, the activities of ERK-1 and ERK-2 were visualized by the transfer of radioactive phosphate to myelin basic protein. Activation measured in the MAPK assay strictly correlated with tyrosine phosphorylation of immunoprecipitated ERK-2 (data not shown). CSF-1-induced signaling to MEK and MAPK was severely impaired in me v /me v mouse-derived macrophages compared with cells obtained from control C57BL/6J mice ( Fig. 2A and B) . The reduction in MEK and MAPK activity was not due to a lower level of expression of the signaling components, as shown by Western blotting (immunoblotting) ( Fig. 2C and D) . These data argue that SHP-1 operates upstream of the MEK-MAPK network. However, CSF-1-mediated Raf-1 activation, as measured in immune complex kinase assays using catalytically inactive MEK as a substrate, was normal in me v /me v mouse-derived macrophages (Fig. 3A) . CSF-1-mediated Raf activation occurred normally in BAC-1.2F5 cells inducibly expressing a dominant inhibitory Ras construct (Fig. 3B) (9) . For Fig. 3B , CSF-1-induced Raf activation was assessed in a coupled assay measuring the ability of Raf to activate MEK. MEK activation, in turn, was measured by its ability to activate MAPK. Taken together, the results in Fig. 3A and B position Raf on a pathway distinct from those of SHP-1 and Ras. They also imply that in macrophages Raf-1 activation is not sufficient for the activation of the MEK-MAPK pathway.
Effect of the me v /me v mutation on CSF-1-stimulated Ras activation. In the BAC-1.2F5 macrophage cell line, CSF-1-induced activation of MEK and MAPK, but not of Raf-1, depends on the presence of a functional Ras protein (9 32 P]phosphate prior to CSF-1 stimulation, cell lysis, and immunoprecipitation with anti-Ras antibodies. Analysis of the nucleotides bound to Ras was performed by thin-layer chromatography. In contrast to the impairment observed in growth factor-mediated MEK and MAPK activation, CSF-1 induced the formation of p21 ras -GTP complexes in both C57BL/6J-and me v /me v mouse-derived macrophages to a comparable extent (Fig. 4) .
Effect of a dominant negative Ras mutant on CSF-1-stimulated SHP-1 activation. To determine whether SHP-1 functions on a separate pathway from, or downstream of, Ras, we used the previously described macrophage cell line BAC-1.2F5. In BAC-1.2F5 cells the basal activity of SHP-1 was greater and the kinetics of activation of the enzyme were faster VOL. 16, 1996 INVOLVEMENT OF SHP-1 IN ACTIVATION OF THE MAPK PATHWAY 5957 than in bone marrow macrophages from control C57BL/6J mice (Fig. 5 ). In addition, at variance with the results obtained with bone marrow-derived macrophages, in BAC-1.2F5 cells SHP-1 was constitutively tyrosine phosphorylated and CSF-1 treatment did not alter the phosphorylation state of the enzyme (data not shown) (84) . In BAC-1.2F5 cells stably transfected with a dominant negative Ras construct (Asn17) under the control of a dexamethasone-inducible promoter (23, 24) , induction of the Ras dominant negative mutant results in a 75% reduction of GTP bound to Ras upon CSF-1 stimulation (9). Dexamethasone pretreatment also prevented SHP-1 activation (Fig. 6) , suggesting that SHP-1 operates downstream of Ras. The expression and the tyrosine phosphorylation of SHP-1 were not affected by dexamethasone pretreatment of BAC-1.2F5 or of Asn17 cells (data not shown).
Effect of the me v /me v mutation on Ras-independent activation of MEK and MAPK induced by LPS. We next sought to determine whether it was possible to activate the MEK-MAPK pathway in me v /me v mouse-derived macrophages by using an agonist that induces activation of the kinases in a Ras-and SHP-1-independent fashion. We have previously shown that bacterial LPS activates MEK and MAPK in a Ras-independent, PKC-and PC-PLC-dependent manner (9) . Macrophages derived from me v /me v or control C57BL/6J mice were treated with LPS for different periods prior to lysis. The activities of SHP-1, MEK, and MAPK were determined as described above. Consistent with the involvement of SHP-1 in Ras-dependent signaling, the phosphatase was not activated upon LPS stimulation of BAC-1.2F5 cells or of C57BL/6J macrophages (data not shown). The kinetics of LPS-mediated MEK and MAPK activation and deactivation were slightly faster in the me v /me v mouse-derived macrophages than in control cells. In contrast to the severe impairment observed with CSF-1, LPS-induced MEK and MAPK activations were not decreased in me v /me v mouse-derived macrophages compared with control cells (Fig. 7A and B) . Ϫ7 M) for 18 h prior to CSF-1 stimulation. The activities of the Raf-1 immunoprecipitates were assayed in an immune complex kinase assay using bacterially expressed, catalytically compromised MEK-1 as a substrate (A) or in a coupled assay measuring the ability of Raf to activate bacterially expressed MEK (B). Catalytically compromised MEK-1 was expressed in bacteria with a histidine tag (His6) and purified by affinity chromatography on nitrilotriacetic acid resin. MEK-1 and ERK-2 were expressed in bacteria with a glutathione-Stransferase tag and purified by affinity chromatography on glutathione agarose followed by the proteolytic cleavage of the MEK-1 and ERK-2 moieties with thrombin. MBP, myelin basic protein.
FIG. 4. Effect of the me
v mutation on CSF-1-induced GTP loading of Ras. Quiescent, 32 P-labeled primary macrophages derived from C57BL/6J controls and from me v /me v mice were stimulated with CSF-1 for different periods. Nucleotides bound to Ras were analyzed by Ras immunoprecipitation followed by thin-layer chromatography. Ori, origin. (Fig.  4) . Thus, SHP-1 does not function on the pathway leading to Ras activation but rather operates on a separate pathway from, or downstream of, this molecule. In support of the latter hypothesis, inducible expression of a dominant negative Ras allele inhibits CSF-1-stimulated SHP-1 activation in the BAC-1.2F5 macrophage cell line (Fig. 6) ; it should be noted, however, that these data cannot be directly compared with those obtained with the primary cultures of bone marrow macrophages from me v /me v and control mice, because of the high level of basal activity and the constitutive tyrosine phosphorylation of SHP-1 in the BAC-1.2F5 cell line. Finally, Ras-independent, LPS-induced MEK and MAPK activation (9) is not impaired in me v /me v cells (Fig. 7A and B) , indicating that the block caused by the absence of a functional SHP-1 resides on the Ras pathway. Taken together, the evidence reported strongly suggests a role for SHP-1 as an intermediate in the Ras-MEK-MAPK pathway.
At present, we can only speculate about the mechanism(s) involved in Ras-dependent, SHP-1-dependent MEK and MAPK activation. One obvious possibility is that SHP-1 targets a tyrosine-phosphorylated MEK kinase activator which is activated by dephosphorylation. Preliminary experiments (see below) suggest that this is not the case. The second possibility is that SHP-1 functions in a modular signaling complex to physically connect the Ras-dependent MEK activator(s) with MEK ( Fig. 8, model I) . In me v /me v mouse-derived macrophages, the enzyme not only is catalytically inactive but also fails to become tyrosine phosphorylated upon CSF-1 stimulation. This growth factor-induced tyrosine phosphorylation of SHP-1 may stimulate the formation of the hypothetical signaling complex or its translocation to its site of activity. Along this line, SHP-1 has recently been shown to associate with the Vav guanine nucleotide exchange factor, with Grb-2 (14), and with Grb-2 and mSOS in resting hematopoietic cells (38) . SHP-1 tyrosine phosphorylation and its association with these signal transducers are increased upon mitogenic stimulation (14, 38) . me v /me v mouse-derived macrophages accumulate much faster than their counterparts obtained from control mice (data not shown). This is consistent with the postulated negative role of SHP-1 in mitogenic stimulation, but it might seem paradoxical because these cells are unable to fully activate the MAPK pathway upon CSF-1 stimulation. In fibroblasts, suppression of MAPK activation by expression of antisense ERK-1 mRNA or by overexpression of kinase-deficient ERK-1 mutants inhibits serum-stimulated proliferation (54); more relevant for this study, the inhibition of epidermal growth factorstimulated MAPK activation observed in human embryonic kidney cells upon overexpression of catalytically inactive SHP-1 correlates with the suppression of cell proliferation (70) . In macrophages, however, suppression of growth factorinduced MAPK activation does not correlate with inhibition of proliferation; we have previously shown that activation of ERK-1 and -2 is suppressed in rapidly growing, v-raf-infected BAC-1.2F5 macrophages (9, 40) . Together with the data reported in this paper, this implies that in macrophages the activation of MAPK is not an absolute requirement for mitogenic signaling, provided that other signal transduction pathways (Raf-dependent pathways in the v-raf-infected cells, pathways normally down-regulated by SHP-1 in the me v /me v mouse-derived macrophages) are constitutively stimulated. Given the pleiotropic effects of CSF-1 on macrophages (the factor is required for proliferation and differentiation), it is conceivable that activation of the Ras-dependent (9) MAPK pathway in these cells may play a role in their differentiation and activation. Consistent with this hypothesis, transgenic mice, in which a suppressor of Ras action (the GAP C-terminal region) was targeted to cells expressing the CSF-1R, showed alterations in the late stages of monocyte/macrophage differentiation and in morphology rather than in cell growth (33) . blocks CSF-1-dependent macrophage differentiation in human bone marrow cultures (65) . Taken together, these reports indicate that Ras signaling may actually be involved in distinct aspects of monocyte terminal differentiation and function. The negative effect of SHP-1 on hematopoietic cell growth is conceivably associated with the dephosphorylation of other signal transducers. Good candidates are the yet-unidentified tyrosine-phosphorylated proteins found associated with Grb-2 in me/me mouse-derived macrophages (14) and the kinases of the Jak family. In this respect, it has been shown that SHP-1 participates in erythropoietin signal transduction by controlling Jak-2 dephosphorylation (37); more germane to this study, Jak-2 is also hyperactivated in granulocyte-macrophage CSFstimulated me v /me v mouse-derived macrophages (19) . The involvement of Jaks in cell proliferation and transformation is supported by observations of D. melanogaster, in which gainof-function mutations of the Jak homolog hopscotch cause hematopoietic tumors (6, 27, 28, 49) .
Ras-and SHP-1-independent activation of Raf-1 by CSF-1 is not sufficient for the activation of MEK and MAPK. The expression of a dominant inhibitory Ras mutant (9) and the lack of an active SHP-1 dramatically reduce MEK and MAPK activation by CSF-1 in macrophages. However, CSF-1-mediated Raf-1 activation occurs normally in both situations (Fig.  3A and B) . Thus, Raf-1 activation is not sufficient to support MEK and MAPK activation in macrophages. Consistently, we have shown earlier that expression of virally activated Raf in BAC-1.2F5 cells does not cause MEK activation unless the cells are stimulated with CSF-1 or LPS or treated with the phosphatase inhibitor okadaic acid (40) . These results suggest that MEK in macrophages is the target of a negative regulator (possibly PP2A) that might be transiently inhibited by stimulation (15) . Inhibition of this putative regulator should occur in a Ras-and SHP-1-dependent manner. In this scenario, Raf-1 would have to be considered a coregulator rather than a direct activator and would cooperate with p21 ras -and SHP-1-derived signals in the CSF-1 pathway (Fig. 8, model II) .
Our data are also consistent with the alternative hypothesis that Raf-1 may not represent the CSF-1-induced MEK kinase activity in macrophages (Fig. 8, model I) . B-Raf (11, 32, 58) and MEKK-1 (42, 43) rophages. B-Raf, however, is not significantly activated upon CSF-1 treatment. MEKK-1 is activated with extremely fast and transient kinetics but in a Ras-independent manner. Thus, consistent with its reported role in the activation of SAPKs rather than MAPKs, MEKK-1 is not the major MEK activator in CSF-1-stimulated BAC-1.2F5 cells. We are currently in the process of characterizing a CSF-1-stimulated, Ras-dependent MEK kinase from BAC-1.2F5 cells. This kinase is obviously a candidate for the SHP-1-dependent MEK activator; in preliminary experiments it does not appear to be subject to tyrosine phosphorylation and dephosphorylation upon CSF-1 treatment (41a). The nature of the intermediate connecting p21 ras to the MEK-MAPK pathway in macrophages remains to be determined. Aside from Raf, Ras interacts with a number of putative downstream targets, including the GAP-NF1 family of GTPase-activating proteins (50, 57, 80) , PI-3-kinase (59) , and the guanine nucleotide exchange factor for Ral, Ral GDS (31, 35, 67) . Preliminary experiments were designed to assess the possible contribution of PI-3-kinase and Ral GDS. Inhibition of PI-3-kinase with wortmannin (41a) and pretreatment of BAC-1.2F5 cells with forskolin (7a), which reportedly increases Ras-Ral GDS association (36) , failed to modulate CSF-1-induced MEK and MAPK activation. Accordingly, it is unlikely that PI-3-kinase or Ral GDS is an intermediate in the Ras-MAPK signaling pathway in macrophages.
Our results confirm the observation that catalytically inactive SHP-1 overexpressed in human embryonic kidney cells suppresses MEK and MAPK activation by the epidermal growth factor receptor (70) and extend this observation to a second receptor tyrosine kinase (CSF-1R) and to primary cells that harbor a mutation of the endogenous enzyme; furthermore, the data showing that CSF-1-mediated Ras activation occurs normally in me v /me v cells and that Ras-independent MEK and MAPK activation is not impaired in these cells strongly suggest that SHP-1 may be an intermediate in the Ras-MEK-MAPK pathway.
These observations emphasize the combinatorial nature of signal transduction in higher eukaryotes, in which the same or very similar molecules are activated by different mechanisms and function in different pathways depending on the cellular background (8, 26, 30, 60) and on the stimulus used (9, 13) . The task will now be to identify the Ras-and SHP-1-dependent MEK activator and the substrate(s) of SHP-1 and of the Raf-1 kinase in CSF-1-stimulated macrophages.
